{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:55:26Z","timestamp":1791262526633,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vitiligo is a chronic autoimmune depigmentation skin disorder characterized by the acquired loss of melanocytes, with a complex multifactorial pathophysiology. Among the potential predisposing factors, some drugs, including monoclonal antibodies, have been associated to disease onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The aim of the present review is to summarize and discuss current literature findings in de novo vitiligo following biological targeting inflammatory cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 18 articles were considered eligible for the present review, and details of demographics, clinical characteristics, vitiligo type and localization, biological drug administered and treatment outcomes were reported.The mean age of the 39 patients was 43 years (\u00b116.3), with a male predominance (62%). Tumor necrosis factor-alpha (TNF\u03b1) inhibitors (infliximab, adalimumab, certolizumab pegol) were the most frequent suspected drugs (&amp;gt;50% of patients), followed by anti-IL-17A (ixekizumab, secukinumab) and anti-IL-12\/23 (ustekinumab). Four cases were linked to anti-IL-4\/13 (dupilumab). The median onset of vitiligo was 5 months post-initiation (range 1.5\u201324), with one-third of cases involving the face and neck, and two cases of segmental vitiligo. Biologic discontinuation or switching occurred in 26% of cases. Regarding outcomes, 41% experienced stabilization, 36% achieved varying degrees of repigmentation, and 8% progressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>While de novo vitiligo is reported as a potential adverse event of biological therapies, evidence for a direct causal relationship remains weak, with cases involving non-anti-TNF\u03b1 agents appearing anecdotal. The co-occurrence of underlying autoimmune comorbidities in these patients points towards a coincidental rather than a causal relationship, highlighting the need for further research to fully elucidate this association.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1879414","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:51Z","timestamp":1791260751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Vitiligo onset following anti-inflammatory biological therapy: a scoping review"],"prefix":"10.3389","volume":"17","author":[{"given":"Maurizio","family":"Romagnuolo","sequence":"first","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]},{"name":"Department of Medical Biotechnologies, University of Siena","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Carlotta","family":"Rossi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tavoletti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Alberti Violetti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico","place":["Milan, Italy"]},{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-025-00670-x","article-title":"Vitiligo","volume":"11","author":"Seneschal","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01249-z","article-title":"The immunology of vitiligo","volume":"26","author":"Turk","year":"","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.06.004","article-title":"The genetic basis of vitiligo","volume":"141","author":"Spritz","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17683","article-title":"Cutaneous side effects of PD-1 inhibitors: A single-center retrospective study","volume":"64","author":"Pozsgai","year":"2025","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2022.11.013","article-title":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice","volume":"150","author":"Sibaud","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/ijd.16356","article-title":"Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib","volume":"62","author":"Romagnuolo","year":"2023","journal-title":"Int J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: Signals from disproportionality analysis of the FDA adverse event reporting system","volume":"23","author":"Raschi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1455050","article-title":"Biologic drugs induced vitiligo: Case reports and review of literature","volume":"15","author":"Shao","year":"2024","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajg.2011.03.001","article-title":"Vitiligo in a patient receiving infliximab for refractory ulcerative colitis","volume":"12","author":"Ismail","year":"2011","journal-title":"Arab J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000324619","article-title":"Vitiligo during treatment of Crohn's disease with adalimumab: Adverse effect or co-occurrence","volume":"3","author":"Posada","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142887","article-title":"Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report","volume":"89","author":"Carvalho","year":"2014","journal-title":"Bras Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.5.620","article-title":"Development of vitiligo during treatment with adalimumab: A plausible or paradoxical response","volume":"27","author":"Jung","year":"2015","journal-title":"Ann Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13498","article-title":"New onset vitiligo following commencement of infliximab in Crohn disease","volume":"47","author":"Luber","year":"2017","journal-title":"Intern Med J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.6.826","article-title":"A type II segmental vitiligo developed under infliximab treatment for ulcerative colitis","volume":"29","author":"Ryu","year":"2017","journal-title":"Ann Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"M\u00e9ry-Bossard","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12852","article-title":"Multiple paradoxical reactions during ixekizumab therapy","volume":"32","author":"Pirro","year":"2019","journal-title":"Dermatol Ther"},{"key":"B20","article-title":"New-onset vitiligo as an unusual cutaneous reaction under ustekinumab therapy in patients with psoriatic arthritis. New-onset vitiligo as an unusual cutaneous reaction under ustekinumab therapy in patients with psoriatic arthritis","volume":"45","author":"Gedikli","year":"2020","journal-title":"Acta Reumatol Port"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13347","article-title":"New onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab","volume":"33","author":"Phan","year":"2020","journal-title":"Dermatol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00964-w","article-title":"New-onset vitiligo during treatment with secukinumab: Report of two cases and review of the literature","volume":"40","author":"Nieto-Benito","year":"2020","journal-title":"Clin Drug Investig"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15102","article-title":"Onset of vitiligo in a psoriasis patient on ixekizumab","volume":"34","author":"Marasca","year":"2021","journal-title":"Dermatol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2021.33.5.474","article-title":"A case of new-onset vitiligo in a healthy volunteer after administration of adalimumab","volume":"33","author":"Yang","year":"2021","journal-title":"Ann Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15314","article-title":"Vitiligo development in a patient with psoriasis vulgaris treated with ixekizumab","volume":"35","author":"Eker","year":"2022","journal-title":"Dermatol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15872","article-title":"Generalized vitiligo in a psoriatic patient treated with ixekizumab","volume":"35","author":"Pathmarajah","year":"2022","journal-title":"Dermatol Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1077681","article-title":"Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature","volume":"13","author":"Su","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19132","article-title":"Vitiligo induced by dupilumab treatment: A case series","volume":"37","author":"Ren","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2024.04575","article-title":"Vitiligo in a patient receiving adalimumab for idiopathic uveitis","volume":"54","author":"De\u011firmenci","year":"2024","journal-title":"Turk J Ophthalmol"},{"key":"B30","unstructured":"Adalimumab\n          \n          2026"},{"key":"B31","unstructured":"Infliximab\n          \n          2026"},{"key":"B32","unstructured":"Certolizumab\n          \n          2026"},{"key":"B33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901358","article-title":"TNF-\u03b1 regulates human plasmacytoid dendritic cells by suppressing IFN-\u03b1 production and enhancing T cell activation","volume":"206","author":"Psarras","year":"2021","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/ijd.ijd_27_22","article-title":"A cross-sectional study of the levels of cytokines IL-6, TNF-\u03b1, and IFN-\u03b3 in blood and skin (lesional and uninvolved) of vitiligo patients and their possible role as biomarkers","volume":"68","author":"De","year":"2023","journal-title":"Indian J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052298","article-title":"Increased tumor necrosis factor (TNF)-\u03b1 and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo","volume":"7","author":"Laddha","year":"2012","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1034\/j.1600-0749.2002.1o049.x","article-title":"New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions","volume":"15","author":"Moretti","year":"2002","journal-title":"Pigment Cell Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased risk of vitiligo following anti-tumor necrosis factor therapy: A 10-year population-based cohort study","volume":"138","author":"Bae","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2022.2131332","article-title":"Vitiligo and Crohn's disease form an autoimmune cluster: Insights from a population-based study","volume":"58","author":"Kridin","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5152\/tjg.2026.25282","article-title":"Co-occurrence of inflammatory bowel disease in patients with vitiligo: A systematic review and meta-analysis","volume":"37","author":"Gu","year":"2026","journal-title":"Turk J Gastroenterol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.047","article-title":"Ocular and auditory comorbidities in patients with vitiligo: A nationwide population-based study in the Republic of Korea","volume":"93","author":"Kim","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s00403-024-02965-7","article-title":"A bidirectional autoimmune cluster between vitiligo and rheumatoid arthritis: A large-scale population-based study","volume":"316","author":"Cohen","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B44","unstructured":"Ixekizumab\n          \n          2026"},{"key":"B45","unstructured":"Ustekinumab\n          \n          2026"},{"key":"B46","unstructured":"Secukinumab\n          \n          2026"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.70113","article-title":"Pilot study of tildrakizumab in the treatment of stable non-segmental vitiligo","volume":"4","author":"Lee","year":"2025","journal-title":"JEADV Clin Pract"},{"key":"B49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0394-1","article-title":"Association between psoriasis and vitiligo: A systematic review and meta-analysis","volume":"20","author":"Yen","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"B50","unstructured":"Dupilumab\n          \n          2026"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4228","article-title":"Association between vitiligo and atopic disorders: a pilot study","volume":"149","author":"Silverberg","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J Cosmet Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:53Z","timestamp":1791260753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2026.1879414"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1879414","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1879414"}}